2-(isopropylamino)ethyl acetate | 35265-11-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(isopropylamino)ethyl acetate
• 英文别名: Ethanol, 2-[(1-methylethyl)amino]-, 1-acetate；2-(propan-2-ylamino)ethyl acetate
• CAS: 35265-11-3
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: MQNQUCSOQMODAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(异丙基氨)乙醇 、 ethyl 3-hydroxy-2-(2,4-dinitrophenyl)but-2-enoate 以 氯仿 为溶剂， 反应 120.0h， 以66%的产率得到N-(2-hydroxyethyl)-N-(2-propyl)ethanamide
  参考文献：
  名称：

  通过伪分子内过程对氨基醇进行无金属O选择性直接酰化

  摘要：

  使用α-芳基-β-酮酸酯对二胺进行酰化反应会在较低受阻氨基上区域选择性地发生。在没有金属催化剂的情况下，使用N-烷基氨基醇进行的酰基转移反应会导致化学选择性的O-酰基化反应。不需要保护氨基。由于拟分子内过程，这些反应有效地进行。

  DOI：

  10.1002/ejoc.201801589

文献信息

• [EN] NAMPT MODULATORS<br/>[FR] MODULATEURS DE NAMPT
  申请人：CYTOKINETICS INC

  公开号：WO2021159015A1

  公开（公告）日：2021-08-12

  Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

  提供了公式（II）的化合物或其药用可接受盐，其中R1、R2、R3、R4、R5、R6和p如本文所定义。还提供了包含公式（II）化合物或其药用可接受盐的药用可接受组合物。还提供了使用公式（II）化合物或其药用可接受盐的方法。
• CONTROLLED RELEASE PREPARATION
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160128945A1

  公开（公告）日：2016-05-12

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

  提供了一种受控释放制剂，其中活性成分的释放受到控制，通过在胃肠道内停留或缓慢迁移来延长时间释放活性成分，采用胶囊化片剂、颗粒或细颗粒的方式，其中活性成分的释放受到控制，并且使用了一种凝胶形成聚合物。所述的片剂、颗粒或细颗粒在含有活性成分的核心颗粒上形成了一个受控释放的涂层。
• Drug composition having active ingredient adhered at high concentration to spherical core
  申请人：Yoneyama Shuji

  公开号：US20060159760A1

  公开（公告）日：2006-07-20

  Granule, fine particle or tablet of excellent leaching property, comprising a drug active ingredient in high content realized by forming a layer containing drug active ingredient on core particles through a combination of a method of dispersing and adhering an active ingredient while spraying or adding a binder with a method of spraying or adding a solution or suspension wherein an active ingredient and a binder are contained so as to effect adhesion. Further, there are provided a drug composition containing such a granule, fine particle or tablet and a process for producing the same.

  该文描述了一种具有良好浸出性的颗粒、细粒或片剂，其中包含高含量的药物活性成分，通过将药物活性成分形成在核心颗粒上的一层，通过将活性成分分散和粘附的方法与喷雾或添加粘合剂的方法相结合，或通过添加含有活性成分和粘合剂的溶液或悬浮液以实现粘附。此外，还提供了一种含有这种颗粒、细粒或片剂的药物组成物和制备该药物组成物的方法。
• Controlled release preparation
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2277510A2

  公开（公告）日：2011-01-26

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

  一种可控制有效成分释放的控释制剂，可通过在胃肠道内停留或缓慢迁移来延长有效成分的释放时间，其方法包括将可控制有效成分释放的片剂、颗粒剂或细颗粒剂与凝胶形成聚合物胶囊化。所述片剂、颗粒剂或细颗粒剂在含有活性成分的核心颗粒上形成一层可控制释放的包衣层。
• DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1602362B1

  公开（公告）日：2016-09-28